The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma

The phase III MPACT trial for metastatic pancreatic cancer (PC) showed improved overall survival (OS), progression free survival (PFS) and response rates (RRs) for first-line nab-paclitaxel (Abraxane) and gemcitabine (the AG combination) compared to gemcitabine monotherapy. The safety and efficacy o...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Gastrointest Oncol
Auteurs principaux: Palacio, Sofia, Hosein, Peter J., Reis, Isildinha, Akunyili, Ikechukwu I., Ernani, Vinicius, Pollack, Terri, Macintyre, Jessica, Restrepo, Maria H., Merchan, Jaime R., Rocha Lima, Caio M.
Format: Artigo
Langue:Inglês
Publié: AME Publishing Company 2018
Sujets:
Short Communication
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5848048/
https://ncbi.nlm.nih.gov/pubmed/29564179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2017.10.12
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires